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ABSTRACT 
Irritable bowel disease is very common colon disease. Deflazacort is one of the best drug with clinical activity against Irritable bowel disease. 
Microsphere system are effectively protect drugs against premature degradation, to localize drug molecules at the target site of action and to 
control the time and rate of release. Mucoadhesive microspheres enhance the bioavailability of orally given drugs by lengthened contact time of 
drug with the intestinal mucosa. The main disadvantage of these microspheres is adherence to the substrate by non-specific interaction. To 
overcome this limitation, microspheres are prepared by emulsification method to treat irritable bowel disease. Chitosan microspheres were 
prepared by Ionotropic Gelation method. Microspheres were coated with Eudragil S using solvent evaporation method. 
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INTRODUCTION 
Colon was considered as a part of body solely responsible for 
absorption of water, electrolyte and temporary storage of 
stools, but now it is accepted as an important site for drug 
delivery. Targeted delivery ensures the direct treatment at 
the disease site, lower dosing, and minimizing side effects. 
Drug targeting to colon is highly desirable for local treatment 
of a variety of bowel diseases. Moreover, dosage forms with 
mucoadhesive properties may prolong the residence time at 
the site of drug absorption. Mucoadhesive microparticulates 
coated with a pH-dependent polymer are proposed to 
initiate the release of the drug at the putative colonic pH 7–
8.1-3 Deflazacort is a drug of choice in Ulcerative colitis with 
proven anti inflammatory and immunosuppressive effect. 
Deflazacort is a corticosteroid that works by acting within 
cells to prevent the release of certain chemicals that are 
important in the immune system. These chemicals are 
involved in producing immune and allergic responses, 
resulting in inflammation by decreasing the release of these 
chemicals in a particular area, inflammation is reduced. 
Deflazacort has a shorter biological half life of 1.1-1.9 hr. 
Thus by using deflazacort microspheres half life is increased 
and provide sustained release of drug for longer duration 
and thus bioavailability problems associated with oral 
administration is also improved and microspheres with 
mucoadhesive properties may prolong the residence time at 
the site of drug absorption.3-4 
MATERIAL AND METHODS 
Material 
Deflazacort was collected as a gift sample from Alcon bio 
sciences PVT Ltd, Mumbai. Eudragit-S 100 obtained from 
Degussa India Pvt Ltd. Sodium Alginate and chitosan were 
received from Loba Chemie Pvt. Ltd (Mumbai, India).  All 
other reagents and chemicals used were of analytical grade. 
Methods 
Preparation of mucoadhesive microsphere of 
Deflazacort 
Chitosan microspheres were prepared by ionotropic gelation 
method.  
Preparation I: Chitosan stock solution (1% w/v) was 
prepared by dissolving chitosan in acetic acid (1% v/v) at 
room temperature.  
Preparation II: The drug and sodium alginate was dissolved 
in 100 ml of water. 
Preparation III: 1% Sodium tripolyphosphate solution was 
prepared. 
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Preparation IV: Solution of preparation I was slowly added 
in preparation III with continuous starring on magnetic 
stirrer.  
Preparation II was added in preparation IV through a 
disposable syringe needle into a gently agitating. The 
dropping rate and falling distance were kept constant. The 
solution was magnetically stirred for half an hour followed 
by filtration and rinsing with distilled water. Gel like beads 
were obtained which was air dried for twenty four hours 
followed by oven drying for six hours at 40˚C. 5-6 
 
Table 1: Formulations of the mucoadhasive microspheres               
Sr. No Formulation Code Deflazacort (mg) 
Chitosan  
(mg) 
Sod. Alginate  
(mg) 
1. F1 10 25 50 
2. F2 10 25 75 
3. F3 10 25 100 
4. F4 10 50 50 
5. F5 10 50 75 
6. F6 10 50 100 
 
Coating of mucoadhasive microspheres 
Microspheres were coated with Eudragil S (ES) using solvent 
evaporation method. mucoadhasive microspheres (50 mg) 
were dispersed in 10 mL of coating solution prepared by 
dissolution of 500 mg of ES in ethanol:acetone (2:1) to give 
5:1 (coat:core ratio). This organic phase was then poured in 
70 mL of light liquid paraffin containing 1% wt/vol Span 80. 
The system was maintained under agitation speed of 1000 
rpm at room temperature for 3 hours to allow for the 
evaporation of solvent. Finally, the coated microsphere were 
filtered, washed with n-hexane, and dried in desiccator.7-8 
Evaluation of microspheres           
Percentage Yield 
The prepared microspheres with a size range of 200-300nm 
were collected and weighed from different formulations. The 
measured weight was divided by the total amount of all non-
volatile components which were used for the preparation of 
the microspheres.5-6 
          
                                            
                                 
      
Drug Entrapment 
The various formulations of the mucoadhasive microspheres 
were subjected for drug content. 10 mg of mucoadhasive 
microspheres from all batches were accurately weighed and 
crushed. The powder of microspheres were dissolved in 10 
ml 7.4 pH Phosphate Buffer and centrifuge at 1000 rpm. This 
supernatant solution is than filtered through whatmann 
filter paper No. 44. After filtration, from this solution 0.1 ml 
was taken out and diluted up to 10 ml with 7.4 pH Phosphate 
Buffer. The percentage drug entrapment was calculated 
using calibration curve method.7-8 
In-vitro wash off test  
The mucoadhesive property of microspheres was evaluated 
by an in vitro adhesion testing method known as the wash-
off test. Freshly excised pieces of intestinal mucosa from 
sheep were mounted onto glass slide. About 100 
microspheres were spread onto wet rinsed tissue specimen 
and immediately thereafter the slides were hung onto the 
arm of a tablet disintegrating machine. Then the machine 
was operated. The tissue specimen was given a slow, regular 
up and down movement in the test fluid at about 37°C 
contained in a vessel of the machine. At the end of 1, 2, 3, 4, 5, 
6, 7,8 hrs the machine was stopped and the number of 
microspheres still adhering to the tissue was counted. The 
test was performed at 0.1N hydrochloric acid solution.  
% Mucoadhesion = (Na-Nl) / Na × 100 
Where, Na = number of microspheres applied; Nl = number 
of microspheres leached out.9-10 
 Measurement of mean particle size 
The mean size of the microspheres was determined by Photo 
Correlation Spectroscopy (PCS) on a submicron particle size 
analyzer at a scattering angle of 90°. A sample (0.5mg) of the 
microspheres suspended in 5 ml of distilled water was used 
for the measurement. 11  
Determination of zeta potential 
The zeta potential of the drug-loaded microspheres was 
measured on a zeta sizer by determining the electrophoretic 
mobility in a micro electrophoresis flow cell. All the samples 
were measured in water at 25°C in triplicate.9-11 
Shape and Surface Characterization of Microspheres by 
Scanning Electron Microscopy (SEM) 
From the formulated batches of microspheres, formulations 
(F3) which showed an appropriate balance between the 
percentage releases were examined for surface morphology 
and shape using scanning electron microscope Jeol Japan 
6000. Sample was fixed on carbon tape and fine gold 
sputtering was applied in a high vacuum evaporator. The 
acceleration voltage was set at 10KV during scanning. 
Microphotographs were taken on different magnification and 
higher magnification (200X) was used for surface 
morphology.10-12  
In-vitro Release Studies 
In vitro drug release in gastrointestinal fluids of 
different pH 
The prepared microsphere was evaluated for in vitro drug 
release. The drug release studies were carried out using USP 
XXII paddle type Dissolution test apparatus. The dissolution 
study was carried out in 900 ml dissolution medium which 
was stirred at 100 rpm maintained at 37±0.2C. The scheme 
of using the simulated fluids at different timing was as 
follows:  
 1st hour: Simulated gastric fluid (SGF) of pH 1.2. 
 2nd and 3rd hour: Mixture of simulated gastric and 
Intestinal fluid of pH 4.5. 
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 4th to 5th hour:  Simulated intestinal fluid (SIF) of pH 6.8. 
 6th hour and onward: SIF pH 7.5 
A weighed quantity of formulation (100 mg) was spread over 
the surface of dissolution media (900 ml) at 37±0.2C. 
Samples were withdrawn at different time interval and 
compensated with same amount of fresh dissolution 
medium. Volume of sample withdrawn was made up to 10ml 
by continuous media. The samples withdrawn were assayed 
spectrophotometrically at 242.0 nm for deflazacort and 
using UV visible spectrophotometer. The release of 
deflazacort was calculated with the help of Standard curve of 
deflazacort.9-12 
Drug release kinetic data analysis 
Several kinetic models have been proposed to describe the 
release characteristics of a drug from matrix. The following 
three equations are commonly used, because of their 
simplicity and applicability. Equation 1, the zero-order 
model equation (Plotted as cumulative percentage of drug 
released vs time); Equation 2, Higuchi’s square-root equation 
(Plotted as cumulative percentage of drug released vs square 
root of time); and Equation 3, the Korsemeyer-Peppas 
equation (Plotted as Log cumulative percentage of drug 
released vs Log time).10-12 
RESULTS AND DISCUSSION 
Evaluation of deflazacort microspheres 
Percentage Yield 
Percentage yield of different formulation was determined by 
weighing the Microspheres after drying.  The percentage 
yield of different formulation was in range of 82.56 – 
93.58%.  
Table 2: Percentage Yield for Different Formulation 
Formulation Percentage Yield 
F1 82.56±0.45 
F2 83.56±0.25 
F3 89.98±0.32 
F4 85.56±0.45 
F5 88.85±0.47 
F6 93.58±0.85 
 
 
Figure 1: Percentage Yield for different formulation 
Drug Entrapment 
The drug entrapment of different formulations was in range 
of 78.05- 83.25% w/w. This is due to the permeation 
characteristics of HPMC that could facilitate the diffusion of 
part of entrapped drug to surrounding medium during 
preparation of deflazacort microspheres. 
Table 3: Drug Entrapment for Different Formulation 
Formulation 
Drug entrapment (% w/w) 
of prepared microsphere 
F1 78.05±0.25 
F2 79.98±0.32 
F3 82.56±0.14 
F4 80.12±0.57 
F5 81.14±0.54 
F6 83.25±0.45 
 
 
Figure 2: Drug Entrapment for Different Formulation 
The maximum Percentage Yield, Drug Entrapment was found 
to be formulation F3. The optimized formulation of batches 
subjected to further studies. 
Results of In-vitro wash off test  
Table 4: Results of In-vitro wash off test 
Formulatio
n code 
1hr 2hr 4hr 6hr 8hr 
F1 78 74 68 65 61 
F2 81 75 69 65 60 
F3 92 85 80 78 75 
F4 85 78 70 65 60 
F5 78 70 65 60 58 
F6 75 68 60 55 45 
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Figure 3: Graph of Results of In-vitro wash off test 
 
Particle size analysis 
The mean size of the microspheres was determined by photo 
correlation spectroscopy (PCS) on a submicron particle size 
analyzer (Horiba Instruments) at a scattering angle of 90°. A 
sample (0.5mg) of the microspheres suspended in 5 ml of 
distilled water was used for the measurement. The results of 
measurement of mean particle size of optimized formulation 
F3 microsphere was found 150.9 nm respectively. 
 
Figure 4: Particle size data of mucoadhesive 
microsphere 
Zeta Potential 
The zeta potential of the drug-loaded microspheres was 
measured on a zeta sizer (Malvern Instruments) by 
determining the electrophoretic mobility in a micro 
electrophoresis flow cell. All the samples were measured in 
water at 25°C in triplicate.  Results of zeta potential of 
optimized formulation F3 microsphere was found -10.7 mV 
respectively. 
 
Figure 5: Zeta potential data of mucoadhesive 
microsphere 
Scanning Electronic Microscopy 
Shape and surface characteristic of Deflazacort microspheres 
exam in by Scanning Electronic Microscopy analysis.  Surface 
morphology of formulation examines at two different 
magnification 55X which illustrate the smooth surface of 
mucoadhesive Microspheres. 
  
Figure 6: Scanning Electronic Microscopy image of 
optimized formulation F-3
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In Vitro drug release 
Table 5: Cumulative % drug release of Deflazacort from plain and coated microsphere at different pH 
S. No. 
  
Dissolution medium 
  
Time (hrs) 
  
% Cumulative Drug Release 
Microsphere Coated microsphere 
1 SGF (pH 1.2) 
 
1 4.8 0.3 
2 2 7.2 0.7 
3  
SGF+SIF(pH 4.5) 
 
3 13.0 1.0 
4 4 18.9 4.2 
5 5 25.7 9.7 
6  
SIF (pH 6.8)  
 
6 37.0 16.2 
    
7 7 58.4 34.3 
8 SIF (pH 7.5) 8 66.7 45.5 
    
9 9 73.1 53.1 
10 10 82.3 62.0 
11 12 88.6 67.8 
 
 
 
Figure 7: Cumulative Percent Drug Released Vs Time 
(Zero Order Plots)  
 
Figure 8: Log Cumulative Percent Drug Remaining Vs 
Time (First Order Plots)
 
 
Figure 9: Log Cumulative Percent Drug Released Vs Log Time (Peppas Plots)  
 
Table 6 Regression Analysis Data of mucoadhasive microspheres Formulation 
Formulation Zero order First order Pappas plot 
F3 y = 6.540x - 10.65 
R² = 0.944 
y = -0.048x + 2.123 
R² = 0.932 
y = 2.406x - 0.587 
R² = 0.975 
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Stability studies 
Stability studies were carried out with optimized 
formulation which was stored for a period of 45 days at 
4±1°C, RT and 40±1°C. The particle size of formulation was 
determined by optical microscopy using a calibrated ocular 
micrometer. The particle size of the microsphere was found 
to increase at RT, which may be attributed to the aggregation 
of microsphere at higher temperature. At 452°C the 
microsphere aggregate i.e. these microsphere were unstable 
at higher temperature like 452°C. Percent efficiency of 
mucoadhesive Microspheres also decrease at higher 
temperature Like 452°C. 
CONCLUSION 
From the result of present study, it can be concluded that 
chitosan based deflazacort mucoadhesive microspheres offer 
a high degree of protection from premature drug release in 
simulated upper GIT conditions and deliver most of the drug 
load in the colon and allow drug release to occur at the 
desired site. Based on the results of the physicochemical 
characterization and in vitro drug release studies, it 
possessed all the required physicochemical characters and 
with drug releases up to 12 h where it released 67.8 % of the 
deflazacort. Thus, chitosan based microspheres are a 
potential system for colon delivery of deflazacort for 
Ulcerative colitis. 
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